CNMD  Conmed Corporation

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Electromedical & Electrotherapeutic Apparatus

Market Cap.

1.29B

Vuru Grade

37.57/100

Current Price

$46.38
+0.47 (+1.02%)

Growth Price

$31.86
Overvalued by 31.31%

Stability Price

$17.50
Overvalued by 62.28%

Company Metrics

  • P/E 59.39
  • P/S 1.76
  • P/B 2.19
  • EPS 0.78
  • Cash ROIC 6.92%
  • Cash Ratio 0.61
  • Dividend 0.8 / 1.81%
  • Avg. Vol. 202,271.00
  • Shares 27.81M
  • Market Cap. 1.29B

Company Description

CONMED Corporation, a medical technology company, provides surgical devices and equipment for minimally invasive procedures and monitoring. The company's products serve the clinical areas of arthroscopy, powered surgical instruments, electrosurgery, cardiac monitoring disposables, endosurgery, and endoscopic technologies. It offers arthroscopy products, including powered resection instruments, art... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

CONMED Corporation Announces First Quarter 2016 Financial Results
Business Wire (press release) - Apr 27, 2016
Further, the contribution from the AirSeal® System was in line with our expectations,” commented Curt R. Hartman, CONMED's President and Chief Executive Officer. “Despite a slow start to the year for capital sales in the international markets, we saw ...
CONMED Corporation Adds Health Care Executive Martha Goldberg Aronson to its ...
Business Wire (press release) - Feb 23, 2016
“We are pleased to welcome Martha to our Board of Directors,” commented Mark Tryniski, Chairman of CONMED's Board of Directors.
Sales of $860.305 expected for CONMED Corporation (NASDAQ:CNMD)
Investor Newswire - 9 hours ago
Since three months ago, 2 analysts have increased their sales estimates for CONMED Corporation (NASDAQ:CNMD) and 2 have lowered their sales estimates.
CONMED Corporation to Announce First Quarter 2016 Financial Results on April ...
Business Wire (press release) - Apr 6, 2016
UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NASDAQ:CNMD) today announced that it will report financial results for the first quarter of fiscal year 2016 after the market close on Wednesday, April 27, 2016.
CONMED Corporation Announces Fourth Quarter and Fiscal Year 2015 Financial Results
Business Wire (press release) - Jan 27, 2016
In addition, gross margin improvement in the second half of the year and lower operating expenses as a result of cost saving initiatives are positive trends we intend to build on entering 2016,” commented Curt R. Hartman, CONMED's President and Chief ...
CONMED Corporation Announces Quarterly Cash Dividend
Business Wire (press release) - Apr 28, 2016
UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NASDAQ:CNMD) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on July 6, 2016 to all shareholders of record as of June 15, 2016.
Earnings Scope: CONMED Corporation (NASDAQ:CNMD)
Markets Daily - Jun 28, 2016
Sell-side research brokers are expecting CONMED Corporation (NASDAQ:CNMD) to report earnings per share of $0.51 for the quarter ending 2016-06-30.
Stock In Limelight: CONMED Corporation (NASDAQ:CNMD) - Equities Focus
CONMED Corporation Announces Annual Meeting of Shareholders
Business Wire (press release) - Mar 7, 2016
UTICA, N.Y.--(BUSINESS WIRE)--CONMED Corporation (NASDAQ: CNMD) today announced that its Annual Meeting of Shareholders will be held at the Company's corporate offices, 525 French Road, Utica, NY on Wednesday, May 25, 2016, at 2:30 p.m.
Recently Issued Stock Ratings For CONMED Corporation (NASDAQ:CNMD)
Fiscal Standard - 16 hours ago
10/22/2015 - CONMED Corporation had its “market perform” rating reiterated by analysts at Northland Securities. They now have a USD 44 price target on the stock.
CONMED Corporation Appoints Nathan Folkert as Vice President and General ...
Business Wire (press release) - Sep 24, 2015
Mr. Folkert brings 15 years of diverse medical device experience to CONMED. Most recently, he served as President of Zimmer's Trauma Division, where he held full P&L responsibility and oversaw sales, marketing, global research and development, ...